Featured Research

from universities, journals, and other organizations

National Jewish Researchers Show Intravenous Immunoglobulin Reduces Steroid Insensitivity, Hospitalizations Of People With Severe Asthma

Date:
March 19, 1999
Source:
National Jewish Medical And Research Center
Summary:
People with severe asthma who are "insensitive" to steroids need less of the medication, fewer "bursts" of it in emergencies and spend less time in the hospital when using intravenous immunoglobulin (IVIG) in conjunction with steroids, according to research published today in the Journal of Allergy and Clinical Immunology.

DENVER-People with severe asthma who are "insensitive" to steroids need less of the medication, fewer "bursts" of it in emergencies and spend less time in the hospital when using intravenous immunoglobulin (IVIG) in conjunction with steroids, according to research published today in the Journal of Allergy and Clinical Immunology.

Researchers found that during the 6-month study, patients had fewer hospitalizations for asthma attacks than in the 6 months prior to the study, even though they used less glucocorticoids, known generally as steroids.

IVIG also was as effective in people whose asthma can be treated with glucocorticoids, as it was in people whose asthma usually doesn't respond to glucocorticoids, or who are "steroid-insensitive." Researchers believe IVIG increases steroid sensitivity of the lungs to steroids, in part, by reducing lung inflammation. "We saw patients whose asthma does very poorly and who needed high doses of steroids to control the disease," said Erwin Gelfand, M.D., a pediatric immunology and asthma specialist and chair of the Department of Pediatrics at National Jewish Medical and Research Center.

While steroid-insensitive patients must take higher doses to achieve minimal control of their disease, they also may become dependent on the medication to breathe normally. Researchers found that by taking IVIG in conjunction with glucocorticoids, patients could use less glucocorticoids more efficiently.

Long-term use of glucocorticoids can stunt growth in children or cause osteoporosis, while IVIG has few side effects. "Compared to steroids, IVIG is not toxic at all," Dr. Gelfand said. "In addition, lowering the amount of steroids a patient takes reduces side effects and the patient's quality of life improves dramatically."

IVIG treatments cost several thousand dollars each month for people with severe asthma, but many health insurance companies cover the cost because, as this study shows, IVIG lowers emergency room and hospital use by patients with severe asthma. Glucocorticoids reduce inflammation in the lungs. IVIG is an antibody that is removed from the plasma portion of blood and is concentrated for use as a medication. IVIG can regulate the immune/inflammatory system and has been shown to reduce inflammation in the lungs.

National Jewish Medical and Research Center is ranked as the best hospital in the United States for respiratory diseases by U.S. News & World Report, 1998-1999.


Story Source:

The above story is based on materials provided by National Jewish Medical And Research Center. Note: Materials may be edited for content and length.


Cite This Page:

National Jewish Medical And Research Center. "National Jewish Researchers Show Intravenous Immunoglobulin Reduces Steroid Insensitivity, Hospitalizations Of People With Severe Asthma." ScienceDaily. ScienceDaily, 19 March 1999. <www.sciencedaily.com/releases/1999/03/990316130947.htm>.
National Jewish Medical And Research Center. (1999, March 19). National Jewish Researchers Show Intravenous Immunoglobulin Reduces Steroid Insensitivity, Hospitalizations Of People With Severe Asthma. ScienceDaily. Retrieved October 22, 2014 from www.sciencedaily.com/releases/1999/03/990316130947.htm
National Jewish Medical And Research Center. "National Jewish Researchers Show Intravenous Immunoglobulin Reduces Steroid Insensitivity, Hospitalizations Of People With Severe Asthma." ScienceDaily. www.sciencedaily.com/releases/1999/03/990316130947.htm (accessed October 22, 2014).

Share This



More Health & Medicine News

Wednesday, October 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Vaccine Trials to Start a in January

WHO: Ebola Vaccine Trials to Start a in January

AP (Oct. 21, 2014) Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe in soon to start trials, the World Health Organization said Tuesday. (Oct. 21) Video provided by AP
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
CDC Issues New Ebola Guidelines for Health Workers

CDC Issues New Ebola Guidelines for Health Workers

Reuters - US Online Video (Oct. 21, 2014) The U.S. Centers for Disease Control and Prevention has set up new guidelines for health workers taking care of patients infected with Ebola. Linda So reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins